ALZA Corporation

ALZA Corporation, headquartered in Mountain View, California, is a leading developer and manufacturer of drug delivery products for the global healthcare industry. ALZA possesses the world’s most extensive portfolio of drug delivery technologies and drug targeting platforms, including oral, transdermal, implantable, and liposomal technologies, applying its delivery technologies to develop and manufacture pharmaceutical products with enhanced therapeutic value for many of the world’s leading pharmaceutical and biotechnology companies. Currently, more than 30 products sold in over 80 countries worldwide utilize ALZA’s drug delivery technology. For more information about ALZA, a wholly-owned subsidiary of Johnson & Johnson, please visit www.alza.com. PRODUCTS & TECHNOLOGY In 1968, Dr. Alejandro Zaffaroni founded ALZA Corporation with the vision that drug delivery technology could add value to pharmaceuticals by precisely controlling the targeting, timing, and dosage of therapeutic compounds. Today, ALZA’s technologies are incorporated into more than 30 products sold globally by its partners in over 80 countries. Products developed by ALZA provide therapeutic benefits to millions of patients worldwide. The company’s osmotic-controlled oral delivery system (OROS®), transdermal (D-TRANS®), and implantable (DUROS®) technologies have been applied in many widely used pharmaceutical products, including Duragesic® (fentanyl) CII, NicoDerm® CQ® (nicotine), Ditropan XL® (oxybutynin), Concerta® (methylphenidate), and Viadur® (leuprolide acetate). Additionally, STEALTH® liposomal technology is designed to enhance the efficacy and reduce the toxicity of intravenously administered drugs through site-specific targeting. ALZA’s novel drug delivery technologies—including E-TRANS® transdermal, Macroflux® transdermal, and ALZAMER® reservoir injectable technologies—offer multiple approaches to improve current and future treatment methods. These new technologies aim to provide convenient and comfortable alternatives for managing proteins, peptides, and new biotechnology products. ALZA is transforming the face of healthcare. As new compounds emerge from biotechnology and genetic research, ALZA’s technologies continue to evolve, providing unique delivery platforms to address challenges and expand the potential of important new therapies.